Denosumab, Romosozumab, and Teriparatide

Table of Contents

  1. Who These Drugs Are For
  2. Two Categories: Antiresorptive vs. Anabolic
  3. Denosumab (Prolia) — How It Works
  4. Denosumab Evidence: The FREEDOM Trial
  5. The Rebound Fracture Problem
  6. Teriparatide (Forteo) — The First Anabolic
  7. Abaloparatide (Tymlos) — The PTHrP Cousin
  8. Romosozumab (Evenity) — The Dual-Action Drug
  9. The Romosozumab Cardiovascular Warning
  10. Sequencing: The Order Actually Matters
  11. Side Effects and Monitoring
  12. Cost, Insurance, and Getting Approved
  13. Questions to Ask Your Doctor
  14. Key Research Papers
  15. Research Papers
  16. Connections

Who These Drugs Are For

If you are reading this page, your DEXA scan probably came back worse than expected, you broke a bone that should not have broken, or your doctor mentioned a drug that sounds expensive and complicated. The three drugs in the title — denosumab, teriparatide, and romosozumab — are the heavy hitters of osteoporosis pharmacology. They are not first-line for a mild bone-density dip. They are for people at high or very high fracture risk: T-score below −2.5 with a recent fragility fracture, multiple vertebral compression fractures, a hip fracture in the last year or two, or a FRAX 10-year major-fracture probability above roughly 20% (or hip-fracture probability above 3%).

These drugs exist because oral bisphosphonates — alendronate, risedronate, ibandronate — do not work for everyone. Some patients cannot tolerate them (reflux, esophagitis). Some absorb them poorly. Some have already been on them for five or ten years and continue to lose bone or sustain fractures. And some arrive at the rheumatologist's office with a T-score of −3.8 and two crushed vertebrae, in which case starting with an oral bisphosphonate is a bit like bringing a garden hose to a house fire. For those patients, the injectable biologics and the bone-building drugs change the trajectory of disease.

This page walks through what each drug does, the pivotal trials, the traps (especially the denosumab discontinuation rebound and the romosozumab cardiovascular signal), how they are sequenced, and what it all costs.

Two Categories: Antiresorptive vs. Anabolic

Bone is constantly remodeled. Osteoclasts chew up old bone (resorption). Osteoblasts lay down new bone (formation). In a healthy young adult the two processes balance. In osteoporosis, resorption outpaces formation and net bone mass falls.

Osteoporosis drugs split into two mechanistic camps:

This distinction is not academic. It drives two practical rules. First, anabolics have caps on how long you can use them — they are sprints, not marathons. Second, whatever gains you build during an anabolic course will evaporate within a year or two unless you follow with an antiresorptive. The drugs are tools in a sequence, not stand-alone solutions.

Denosumab (Prolia) — How It Works

Denosumab is a fully human monoclonal antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand). RANKL is the signal osteoblasts and other cells send to osteoclast precursors saying "grow up and start dissolving bone." When denosumab binds RANKL, that signal never reaches the receptor (RANK) on the osteoclast precursor. No signal, no mature osteoclast, no resorption. Within days of a dose, markers of bone turnover (CTX, P1NP) fall to near-undetectable levels.

The dosing is one of its selling points: 60 mg subcutaneous injection every six months. Your rheumatologist, primary care doctor, or infusion nurse gives it — most often in the back of the upper arm, thigh, or abdomen. There is no requirement to stand upright for thirty minutes, no esophageal irritation, no fasting. For patients who failed oral bisphosphonates for GI reasons, denosumab solved a real problem.

Prolia is the 60 mg formulation for osteoporosis. Xgeva, the same molecule at 120 mg monthly, is used in cancer-related skeletal disease — different dose, different indication. If anyone ever writes you a prescription for Xgeva for osteoporosis, that is a mistake.

Denosumab Evidence: The FREEDOM Trial

The pivotal study was FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months), published by Cummings and colleagues in the New England Journal of Medicine in 2009. Nearly 8,000 postmenopausal women with T-scores between −2.5 and −4.0 were randomized to denosumab or placebo for three years. The results were definitive:

The FREEDOM Extension trial followed a subset for an additional seven years — ten years of denosumab in total. Unlike bisphosphonates, where BMD tends to plateau, denosumab produced continuous BMD gains year after year. By year ten, lumbar-spine BMD was up roughly 21% from baseline and hip BMD roughly 9%. Fracture rates stayed low throughout. For a drug given twice a year with few side effects, these numbers are genuinely impressive.

The Rebound Fracture Problem

Here is the catch that makes denosumab both loved and feared by endocrinologists. When you stop taking it, the effect does not just fade — it reverses violently. Within six to twelve months of a missed dose, osteoclast activity rebounds to levels higher than baseline, bone turnover markers spike, BMD falls rapidly back toward pre-treatment values, and patients experience a wave of multiple vertebral compression fractures. Cases of patients sustaining four, five, or even eight simultaneous new vertebral fractures have been reported in the literature.

This is not theoretical. Cummings et al. re-analyzed FREEDOM data in 2018 and showed that patients who discontinued denosumab had vertebral fracture rates that rose to and then exceeded the placebo group within two years of stopping. The mechanism is biological: denosumab never actually kills osteoclast precursors, it just silences their signaling. When the antibody washes out, a large population of un-stimulated precursors floods into action all at once.

The practical rules that follow from this are absolute:

If you ever find out your insurance changed and Prolia needs prior auth again, do not wait passively. Call your rheumatologist that day. The rebound clock is already ticking.

Teriparatide (Forteo) — The First Anabolic

Teriparatide is recombinant parathyroid hormone 1-34 — the first 34 amino acids of your own PTH, the same hormone your parathyroid glands secrete. Chronic elevation of PTH (as in hyperparathyroidism) dissolves bone. But pulsed PTH exposure — a once-daily injection that peaks and falls within hours — does the opposite. It preferentially activates osteoblasts, which build new bone faster than osteoclasts can remove it. For the first time in osteoporosis treatment, patients were not just preserving bone but making new trabecular microarchitecture.

Dosing: 20 micrograms subcutaneously once daily, from a prefilled multi-dose pen that looks like an insulin injector. You give it to yourself in the thigh or abdomen, usually in the evening. Most patients get comfortable with the self-injection within a few days.

The pivotal Fracture Prevention Trial (FPT), published by Neer and colleagues in NEJM in 2001, randomized 1,637 postmenopausal women with prior vertebral fractures to teriparatide or placebo. At a median of 21 months of follow-up, teriparatide cut new vertebral fractures by 65% and non-vertebral fragility fractures by 53%. The trial was stopped early when rat studies showed osteosarcomas at very high lifetime doses. Follow-up data in humans has not shown an osteosarcoma signal at therapeutic exposure, and the FDA removed the black-box warning in 2020.

Two hard caps: the lifetime maximum is two years, and you only get one two-year course. The two-year limit is partly regulatory history and partly biological — after 18–24 months the anabolic window starts to close as osteoclasts catch up. At the end of the course, BMD gains are real but will vanish without a follow-on antiresorptive. Zoledronic acid or denosumab is the standard choice.

Abaloparatide (Tymlos) — The PTHrP Cousin

Abaloparatide is a synthetic analog of PTH-related protein (PTHrP), a paracrine signaling molecule involved in skeletal development. It binds the same receptor (PTH1R) as teriparatide but with a different conformational preference that biases the receptor toward the anabolic signaling branch. In theory, this means more bone formation for less resorption per unit of dose.

Dosing: 80 micrograms subcutaneously daily, also via prefilled pen, also capped at 18–24 months.

The ACTIVE trial (Miller et al., JAMA 2016) randomized 2,463 postmenopausal women with osteoporosis to abaloparatide, teriparatide, or placebo for 18 months. Abaloparatide reduced new vertebral fractures by 86% and non-vertebral fractures by 43% versus placebo. Compared head-to-head with teriparatide, abaloparatide produced numerically greater hip BMD gains and less hypercalcemia, though the two drugs have never been compared with fracture endpoints in a powered trial. In practice, abaloparatide and teriparatide are interchangeable in most patients; the choice often comes down to insurance formulary and co-pay.

Romosozumab (Evenity) — The Dual-Action Drug

Romosozumab is a humanized monoclonal antibody against sclerostin, a protein secreted by osteocytes (the mature bone cells embedded in mineralized bone) that normally suppresses the Wnt signaling pathway in osteoblasts. Sclerostin is, in effect, bone's built-in brake on construction. Remove the brake and osteoblasts proliferate and lay down matrix. But the biology has a second dimension: the same Wnt signaling that drives osteoblasts also, indirectly, reduces RANKL and therefore slows osteoclasts. Romosozumab is simultaneously anabolic and antiresorptive — the only approved drug that does both.

Dosing: 210 mg subcutaneously once monthly for 12 months, delivered as two 105 mg injections back-to-back (your nurse will give them in adjacent sites). After the 12-month course you must transition to an antiresorptive — alendronate, zoledronic acid, or denosumab — or nearly all the BMD gains will be lost within a year.

Two pivotal trials:

These are, on paper, the best fracture numbers any osteoporosis drug has ever produced. Romosozumab is the drug of choice for patients with very high fracture risk — recent hip fracture, multiple vertebral fractures, T-score below −3.5 — who need the biggest possible early density gain.

The Romosozumab Cardiovascular Warning

ARCH also produced a signal that made regulators nervous. Over 12 months, romosozumab patients had more major adverse cardiovascular events (cardiac death, non-fatal myocardial infarction, non-fatal stroke) than alendronate patients: 2.5% vs. 1.9%. The absolute difference was small, the numbers were not statistically overwhelming, and FRAME (which compared romosozumab to placebo rather than alendronate) did not show the same imbalance. But the FDA took the signal seriously and added a boxed warning when Evenity was approved in 2019.

Practical rules:

For a 72-year-old woman with a recent hip fracture and no CV history, the fracture-prevention benefit clearly outweighs the CV risk. For a 78-year-old diabetic with three prior stents and ongoing angina, it does not. Know which patient you are.

Sequencing: The Order Actually Matters

For decades, osteoporosis was treated as "pick one drug, stay on it." The modern understanding is that drugs should be deployed in sequences designed to maximize lifetime BMD and minimize fracture risk. The single most important principle is this:

Anabolic first, then antiresorptive. Not the reverse.

Evidence from several crossover studies (including the DATA-Switch trial) showed that patients who got teriparatide or romosozumab after long prior bisphosphonate exposure had blunted anabolic responses. Prolonged osteoclast suppression before giving an anabolic agent partially closes the window of opportunity — osteoblasts need their osteoclast partners to cycle normally before they can be maximally stimulated. Going the other direction — anabolic first, then locking in the gains with an antiresorptive — produces substantially larger BMD increases.

A few concrete sequences used in practice:

The take-home: if your doctor starts you on alendronate now and then, five years from now, thinks about teriparatide, the teriparatide will work less well than it would have if used first. This is a worth-pushing-on conversation at diagnosis.

Side Effects and Monitoring

Denosumab. Common: mild injection-site reactions, back pain, muscle ache, eczema. Uncommon but serious: hypocalcemia (especially in patients with chronic kidney disease — always correct low calcium and vitamin D before dosing), skin infections including cellulitis, atypical femoral fractures (rare, shared with bisphosphonates), and osteonecrosis of the jaw (ONJ, roughly 0.05% annual risk; see dental guidance below).

Teriparatide and abaloparatide. Common: transient nausea (first injections), leg cramps, mild dizziness on standing after early doses, headache. Monitor serum calcium — mild hypercalcemia is common and usually benign. Contraindicated in Paget disease of bone, unexplained elevations of alkaline phosphatase, prior skeletal radiation, and active or prior bone cancer.

Romosozumab. Common: arthralgia, headache, injection-site reactions. Serious: the cardiovascular signal above, plus ONJ and atypical femoral fractures (very rare). Like denosumab, hypocalcemia needs to be corrected before starting.

Osteonecrosis of the jaw (ONJ) is rare with all three drugs at osteoporosis doses but real. Get a dental cleaning and any needed extractions or implants done before starting if possible, maintain good oral hygiene throughout, and tell your dentist which drug you are on before any invasive procedure. Most rheumatologists do not require stopping Prolia before routine dental work; for major surgery the timing can be coordinated.

Monitoring. DEXA every 1–2 years, bone turnover markers (CTX, P1NP) in selected cases, serum calcium and 25(OH)D at baseline and periodically, and calcium 1000–1200 mg/day plus vitamin D 800–1000 IU/day throughout. See the calcium, vitamin D, and protein article for details.

Cost, Insurance, and Getting Approved

List prices (U.S., 2025–2026 range; your actual cost depends on insurance, Medicare Part B vs. Part D, and manufacturer copay cards):

Prior authorization is the rule, not the exception. Every payer wants documentation of (1) a qualifying DEXA T-score or a fragility fracture, (2) failure, intolerance, or contraindication to oral bisphosphonates for the anabolics, (3) adequate calcium and vitamin D, and (4) a plan for the follow-on antiresorptive with romosozumab and teriparatide. Appeals succeed more often than people assume — do not take a first denial as final. A well-written appeal citing FREEDOM, ACTIVE, FRAME, or ARCH and documenting why the patient needs this specific drug (recent hip fracture, stacked vertebral fractures, failed oral therapy) wins a majority of the time.

Manufacturer patient-assistance programs (Amgen Assist, Radius Health Patient Support, Lilly Cares) can cover the drug entirely for uninsured patients who meet income thresholds. Ask your prescriber's office for the forms — most rheumatology practices do these weekly.

Questions to Ask Your Doctor

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on these three drug classes:

  1. Denosumab and the FREEDOM trial
  2. Denosumab discontinuation and rebound vertebral fractures
  3. Teriparatide and the Fracture Prevention Trial
  4. Abaloparatide and the ACTIVE trial
  5. Romosozumab: FRAME and ARCH trials
  6. Romosozumab cardiovascular adverse events
  7. Sequential therapy: anabolic followed by antiresorptive
  8. DATA-Switch: teriparatide and denosumab sequencing
  9. Sclerostin, Wnt signaling, and bone formation
  10. Osteonecrosis of the jaw with antiresorptive therapy

Connections

Back to Table of Contents